Marinomed Biotech AG. Stock Analysis MARI.VI

Marinomed Biotech AG is a biopharmaceutical company, which engages in the development of therapies based on patent protected technology platforms. The firm operates in two segments such as Virology and Immunology. The company develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose, platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients, this technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The firm also offers products for the treatment of influenza, combination products for asthmatics, and others. The firm also develops treatments for type I allergies and autoimmune diseases.